Skip to main content
BMJ Open Access logoLink to BMJ Open Access
. 2018 Jul 16;28(3):297–304. doi: 10.1136/tobaccocontrol-2018-054263

Productivity burden of smoking in Australia: a life table modelling study

Alice J Owen 1, Salsabil B Maulida 1,2, Ella Zomer 1, Danny Liew 1
PMCID: PMC6580760  PMID: 30012640

Abstract

Objectives

This study aimed to examine the impact of smoking on productivity in Australia, in terms of years of life lost, quality-adjusted life years (QALYs) lost and the novel measure of productivity-adjusted life years (PALYs) lost.

Methods

Life table modelling using contemporary Australian data simulated follow-up of current smokers aged 20–69 years until age 70 years. Excess mortality, health-related quality of life decrements and relative reduction in productivity attributable to smoking were sourced from published data. The gross domestic product (GDP) per equivalent full-time (EFT) worker in Australia in 2016 was used to estimate the cost of productivity loss attributable to smoking at a population level.

Results

At present, approximately 2.5 million Australians (17.4%) aged between 20 and 69 years are smokers. Assuming follow-up of this population until the age of 70 years, more than 3.1 million years of life would be lost to smoking, as well as 6.0 million QALYs and 2.5 million PALYs. This equates to 4.2% of years of life, 9.4% QALYs and 6.0% PALYs lost among Australian working-age smokers. At an individual level, this is equivalent to 1.2 years of life, 2.4 QALYs and 1.0 PALY lost per smoker. Assuming (conservatively) that each PALY in Australia is equivalent to $A157 000 (GDP per EFT worker in 2016), the economic impact of lost productivity would amount to $A388 billion.

Conclusions

This study highlights the potential health and productivity gains that may be achieved from further tobacco control measures in Australia via application of PALYs, which are a novel, and readily estimable, measure of the impact of health and health risk factors on work productivity.

Keywords: public policy, prevention, economics


Video 1.

Download video file (20.8MB, mp4)
DOI: 10.1136/tobaccocontrol-2018-054263.video01

Introduction

The Global Burden of Disease study demonstrated that smoking continues to exert a significant mortality burden, with worldwide smoking-attributable deaths increasing by 20% since 1990.1 In Australia, following adoption of a series of tobacco control measures,2 age-standardised smoking prevalence decreased from 30.8% to 16.8% from 1980 to 2012.3 However, given population growth, this still represents a substantial number of smokers and a large burden of tobacco-related disease, with >15 000 Australians projected to succumb to premature tobacco-related death each year.4

The healthcare costs of tobacco-related morbidity and mortality (ie, the costs of treating smoking-related illnesses in those who smoke) have been well described, with around 15% of healthcare expenditure attributed to smoking in high-income countries.5 However, these direct costs represent only a proportion of the adverse economic impact of tobacco smoking. Indirect costs include second-hand smoke exposure, costs to employers arising from absenteeism and lost productivity due to smoking among their workforce, welfare benefits associated with supporting those with chronic smoking-related illness and smoking-attributable fires. Less readily quantifiable societal burdens include the social and emotional impact of smoking-related mortality and morbidity on family and loved ones. Of the indirect costs, productivity losses are substantial, but often of lower profile. In Australia in the financial year 2004/2005, it was estimated that the productivity losses associated with smoking was $A8 billion, which far outweighed the $A1.8 billion in direct healthcare costs of smoking.6

Price-based tobacco control measures (such as tobacco taxes) have been shown to be the most effective method for reducing tobacco consumption.7 However, tobacco consumption also confers economic benefits, including income generated as a result of the production and consumption of tobacco and tobacco taxes accrued by governments. These counterbalancing financial issues are often raised when governments are considering tobacco control measures.

In order to provide a clearer understanding of the macro-economic impact of productivity loss due to smoking, we undertook a study that uses a novel measure developed by our group, productivity-adjusted life years (PALYs),8 to examine the productivity burden of smoking in a contemporary Australian setting.

Methods

We used life table modelling and decision analysis9 to examine the impact of smoking on years of life, quality-adjusted life years (QALYs) and PALYs lived among Australians of working age. PALYs are a construct similar to QALYs, but with years of life lived penalised for time spent with reduced work productivity (instead of reduced quality of life) as a result of ill health.8 Akin to utilities that quantify quality of life, ‘productivity indices’ represent the productivity of an individual in proportional terms, ranging from 1.0 (100% productive) to 0 (completely non-productive). Productivity indices may change, for example, with age and/or ill health.

Life tables were constructed using age-specific and sex-specific rates of mortality for smoking and non-smoking adults aged 20–69 years, based on the 2016 Australian population (see online supplementary appendix 1 and table 1). The cohorts were followed until death or age 70 years. The 20–69 years age range was chosen to reflect the ages where people are commonly engaged in paid employment. Analyses were then repeated with the smoking cohort assumed to be non-smokers, and years of life, QALYs and PALYs lived were recalculated. The differences in these measures between the two cohort simulations represented the years of life, QALYs and PALYs lost to smoking.

Table 1.

Modelled population

Age group (years) Males Females
 n* Smoking prevalence† EFT %‡  n* Smoking prevalence† EFT%‡
20–24 851 818 0.162 54.1 807 634 0.173 48.7
25–29 885 390 0.255 79.7 873 715 0.142 57.2
30–34 876 875 0.255 79.7 874 000 0.142 57.2
35–39 785 670 0.222 84.3 790 262 0.141 55.3
40–44 819 943 0.222 84.3 835 414 0.141 55.3
45–49 774 379 0.207 78.0 789 310 0.172 56.9
50–54 769 307 0.207 78.0 788 657 0.172 56.9
55–59 714 584 0.183 68.2 736 359 0.129 49.2
60–64 632 862 0.183 52.2 653 546 0.129 33.6
65–69 570 582 0.111 33.6 582 977 0.069 17.7
Total 7 681 410 6 924 240

*Australian population at 2015.

†Smoking prevalence data from the Australian National Health Survey 2014–2015.13

‡Percentage of total EFT workers from Australian workforce participation data.15

EFT, equivalent full time.

Supplementary data

tobaccocontrol-2018-054263supp001.pdf (84.4KB, pdf)

Within each of the smoking and non-smoking cohorts, we created separate life tables with 1 year cycles for 20 sex-and-age subcohorts, with age being stratified into ten 5-year age bands: 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64 and 65–69 years. The starting age in each subcohort was assumed as the mid-point of the age group (eg, 22 years for age group 20–24 years, 27 years for age group 25–29 years).

For each sex-age cohort, specific mortality rates (by age, sex and smoking status) were applied, as well as smoking-related utilities derived from health-related quality of life measures10 and productivity indices calculated from previously reported rates of absenteeism and presenteeism in smoking compared with non-smoking workers.11

Analyses assuming a 10%, 25%, 50%, 75% and 90% reduction in current smoking prevalence rates were also undertaken.

Data sources

Age-specific and sex-specific mortality rates for single-year age bands were obtained from the Australian General Record of Incidence of Mortality data for 2015.12 Smoking prevalence data were drawn from the Australian National Health Survey 2014–2015.13 Probabilities of death for smokers and non-smokers were calculated from mortality risk in the wider population and population-attributable risk percentage (proportion of all deaths occurring in a population that is attributable to smoking) reported by Peto et al,14 and extrapolated above and below the age of 35 years using exponential equations for male and female smokers and non-smokers. The sex-specific and age-specific probabilities of death for smokers and non-smokers are listed in online supplementary appendix 1.

For the modelling of QALYs, we derived utility decrements due to smoking from a 2010 US study examining trends in health-related quality of life (assessed using the EuroQol 5D (EQ-5D) quality of life tool) associated with smoking by Jia and Lubetkin.10

Productivity decrements due to smoking were estimated from a study by Bunn et al examining productivity loss due to smoking.11 This study found that smokers missed more days at work (absenteeism) (6.7 vs 4.4 days/year) and experienced more unproductive days (presenteeism) (3.2 vs 1.8 days/year) compared with non-smokers. As annual working days varies by age and sex, Australian workforce participation data15 (proportions in full-time and part-time work) were used to calculate sex-specific weighted-average maximum working days in a year among Australians aged 20–69 years. The age-specific and sex-specific productivity indices were then calculated by applying productivity penalties of 0.957 for non-smokers and 0.932 for smokers (calculated from Bunn et al,11 as above) to the age-specific workforce participation rates15 (see online supplementary appendix 2). Assessment of upper and lower bound estimates for PALYs were drawn from 95% CIs for smoking-related work absences reported by Weng et al, which found that current smokers were absent from work for 1.54–3.95 more days per year than non-smokers.16 For these upper and lower estimates, presenteeism data were not varied.

The cost of lost productivity due to smoking was estimated by assignment of a cost for each PALY, which was derived from total Australian gross domestic product (GDP) in 2016 ($A1 474 705 million)17 divided by the estimated number of equivalent full-time (EFT) Australian workers in 2016 (n=9 411 998).15 The figure for 2016 was $A157 000.

Results

Excess mortality burden attributable to smoking

Among Australians currently aged 20–69 years who smoke and are followed up until age 70 years, the estimated number of deaths attributable to their smoking was 277261 in males and 129277 in females, equating to 61.7% and 61.8% of the predicted number of total deaths among smoking males and smoking females, respectively (table 2). The 406538 excess smoking-attributable deaths represented 23.1% of all deaths predicted to occur among the whole population aged 25–69 years, if followed to age 70 years.

Table 2.

Deaths in Australian smokers and non-smokers over working life

Deaths in total pop’n status quo Remainder
alive
Deaths in smokers status quo Smoking-attributable deaths Attributable risk %* PAR%†
Males (years)
 20–24 136 451 715 367 44 411 26 618 59.9 19.5
 25–29 156 353 729 037 72 258 43 473 60.2 27.8
 30–34 152 816 724 059 70 932 42 905 60.5 28.1
 35–39 129 128 656 542 54 463 33 158 60.9 25.7
 40–44 130 441 689 502 55 381 33 962 61.3 26.0
 45–49 115 149 659 230 46 869 29 045 62.0 25.2
 50–54 1 05 325 663 982 43 557 27 433 63.0 26.0
 55–59 82 686 631 898 31 991 20 636 64.5 25.0
 60–64 56 286 576 576 22 826 15 331 67.2 27.2
 65–69 21 981 548 601 6618 4700 71.0 21.4
Male total 1 086 616 6 594 794 449 304 277 261 61.7 25.5
Females (years)
 20–24 87 016 720 618 29 806 17 839 59.8 20.5
 25–29 89 793 783 922 26 327 15 823 60.1 17.6
 30–34 88 471 785 529 26 110 15 790 60.5 17.8
 35–39 78 008 712 254 23 058 14 038 60.9 18.0
 40–44 79 715 755 699 23 709 14 516 61.2 18.2
 45–49 74 523 714 787 26 261 16 236 61.8 21.8
 50–54 68 467 720 190 24 626 15 519 63.0 22.7
 55–59 52 076 684 283 15 419 9990 64.8 19.2
 60–64 38 471 615 075 11 088 7488 67.5 19.5
 65–69 13 877 569 100 2855 2039 71.4 14.7
Female total 670 417 6 253 823 209 260 129 277 61.8 19.3
Total 1 757 033 13 656 251 658 564 406 538 61.7 23.1

Deaths are n.

*Attributable risk %=((deaths in smoker population−deaths in non-smoker population)/deaths in smoker population)×100%.

†PAR%=((deaths in smoker population−deaths in non- smoker population)/deaths in total population)×100%.

PAR, population attributable risk.

If smoking prevalence in the working age population was half of what it currently is, 203 629 smoking-related deaths could be averted in the working age population if followed to age 70 years (table 6). 

Table 6.

Effect of proportional reductions in smoking prevalence on working lifetime national productive capacity among the Australian adult population of 2015

Smoking prevalence reduction (%) Deaths averted QALYs gained PALYs gained Value of PALY gain
($A billion)
10↓ 40 644 602 877 247 514 38.8
25↓ 101 635 1 507 193 618 786 97.0
50↓ 203 269 3 014 386 1 237 572 193.9
75↓ 304 904 4 521 580 1 856 358 290.9
90↓ 365 884 5 425 896 2 227 630 349.0

Data are n or value ($A of productivity gain) across a variety of hypothetical reductions in smoking prevalence (assumed to occur across all age groups and in both sexes).

PALY,  productivity-adjusted life years; QALY,  quality-adjusted life years.

Years of life lost to smoking

The estimated years of life lived by the smoking and (hypothetically) non-smoking cohorts are summarised in table 3. Overall, it was estimated that smoking at current prevalence reduced the number of years of life lived by 2 227 326 years among males and 914 602 years in females. The total reduction in 3 141 928 years of life lived equated to a 4.2% loss among smokers, and represented a 0.9% loss among the whole population. This equated to 1.2 years of life lost per smoker.

Table 3.

Years of life (YOL) lived by working age Australians

Age group YOL lived by smoking cohort status quo Total population YOL lived status quo YOL lost to smoking % YOL lost due to smoking status quo % YOL lost with 50% reduction in smoking
Males (years)
 20–24 6 145 373 39 307 975 265 535 4.1 2.1
 2 5–29 8 950 587 36 344 717 425 928 4.5 2.3
 30–34 7 780 771 31 707 597 408 948 5.0 2.6
 35–39 5 237 777 24 645 072 300 038 5.4 2.8
 40–44 4 614 212 21 773 435 282 121 5.8 3.0
 45–49 3 324 052 16 881 433 214 886 6.1 3.1
 50–54 2 582 922 13 133 827 171 223 6.2 3.2
 55–59 1 537 322 8 852 002 101 095 6.2 3.2
 60–64 849 051 4 865 887 50 682 5.6 2.9
 65–69 180 374 1 680 018 6870 3.7 1.9
All males 41 202 441 199 191 963 2 227 326 5.1 2.6
Females (years)
 20–24 6 409 464 37 795 327 156 139 2.4 1.2
 25–29 5 078 772 36 593 269 136 914 2.6 1.3
 30–34 4 470 811 32 294 539 134 049 2.9 1.5
 35–39 3 473 004 25 322 584 113 481 3.2 1.6
 40–44 3 106 410 22 683 205 107 010 3.3 1.7
 45–49 2 933 165 17 567 640 106 847 3.5 1.8
 50–54 2 290 447 13 741 266 88 225 3.7 1.9
 55–59 1 160 534 9 302 586 45 350 3.8 1.9
 60–64 638 150 5 672 105 23 559 3.6 1.8
 65–69 116 448 1 728 512 3028 2.5 1.3
All females 29 677 206 202 701 034 914 602 3.0 1.5
Total 70 879 647 401 892 998 3 141 928 4.2 2.2

Data are n or % of years of life lost at current smoking prevalence, or years of life gained (n) with a hypothetical 50% reduction in smoking prevalence across all ages and sex.

Quality-adjusted life years lost to smoking

The estimated QALYs lived by the smoking and (hypothetically) non-smoking cohorts are summarised in table 4. Overall, it was estimated that smoking reduced the number of QALYs by 3 849 150 among males and 2 179 623 among females, equating to 2.4 QALYs lost per male smoker and 2.3 QALYs lost per female smoker over the remainder of their working lifetime. The total reduction in 6 028 773 QALYs equated to a 9.4% loss among smokers, and a 2.1% loss among the whole population.

Table 4.

The impact of smoking on QALYs

Age group QALYs smokers status quo QALYs non-smokers QALYs lost to smoking QALYs lost per smoker % QALYs lost QALYs gained with 50% reduction in smoking prevalence
Males (years)
 20–24 5 151 031 29 339 229 520 753 3.8 9.2 260 377
 25–29 7 453 501 24 098 836 795 094 3.5 9.6 397 547
 30–34 6 444 321 20 939 735 722 970 3.2 10.1 361 485
 35–39 4 306 803 16 868 553 506 589 2.9 10.5 253 294
 40–44 3 755 848 14 774 434 459 993 2.5 10.9 229 997
 45–49 2 682 939 11 578 168 339 357 2.1 11.2 169 679
 50–54 2 083 241 8 992 229 264 037 1.7 11.2 132 018
 55–59 1 238 278 6 211 331 153 000 1.2 11.0 76 500
 60–64 681 784 3 382 554 75 875 0.7 10.0 37 938
 65–69 144 119 1 246 204 11 481 0.2 7.4 5741
All males 33 941 864 137 431 273 3 849 150 2.4 10.2 1 924 575
Females (years)
 20–24 5 367 135 27 756 781 439 301 3.1 7.6 219 651
 25–29 4 225 511 27 713 660 361 132 2.9 7.9 180 566
 30–34 3 699 805 24 341 905 328 808 2.6 8.2 164 404
 35–39 2 853 714 18 985 742 262 688 2.4 8.4 131 344
 40–44 2 527 472 16 852 454 238 764 2.0 8.6 119 382
 45–49 2 367 114 12 496 402 228 757 1.7 8.8 114 378
 50–54 1 847 075 9 757 885 179 925 1.3 8.9 89 963
 55–59 934 645 6 913 003 89 209 0.9 8.7 44 605
 60–64 512 375 4 238 671 44 796 0.5 8.0 22 398
 65–69 93 042 1 339 625 6242 0.2 6.3 3121
All females 24 427 888 150 396 127 2 179 623 2.3 8.2 1 089 812
Total 58 369 753 287 827 400 6 028 773 2.4 9.4 3 014 386

Data are n or % of QALY lost at current smoking prevalence, or potential QALY gained (n) with a hypothetical 50% reduction in smoking prevalence across all ages and sex.

QALY, quality-adjusted life years.

Productivity-adjusted life years lost to smoking

The estimated PALYs lived by the population are summarised in table 5. Overall, it was estimated that smoking reduced the number of PALYs by 1 711 214  among males and 702 931 among females. The total reduction in 2 475 144 PALYs equated to a 56.0% loss among smokers (with a range of 5.4%–7.1% when upper and lower absenteeism estimates were applied to the model), and a 1.3% loss among the whole population as well as 1.0 PALY lost per smoker, calculated by dividing the total PALYs lost among smokers by the number of smokers in the population at the start of the modelled period.

Table 5.

The impact of smoking on PALYs in Australian adults over working life

Age group PALYs smokers status quo PALYs non-smokers PALYs lost to smoking % PALYs lost PALYs lost per smoker PALYs gained with 50% reduction in smoking prevalence
Males (years)
 20–24 4 067 800 22 322 890 247 604 5.7 1.8 123 802
 25–29 5 995 490 18 629 334 380 994 6.0 1.7 190 497
 30–34 5 130 166 15 999 475 346 165 6.3 1.5 173 082
 35–39 3 365 515 12 634 406 239 675 6.6 1.4 119 838
 40–44 2 834 059 10 672 183 211 217 6.9 1.2 105 609
 45–49 1 922 042 7 935 712 149 449 7.2 0.9 74 724
 50–54 1 373 426 5 680 150 109 286 7.4 0.7 54 643
 55–59 711 179 3 433 953 57 992 7.5 0.4 28 996
 60–64 324 373 1 564 574 26 076 7.4 0.2 13 038
 65–69 56 387 481 685 3756 6.2 0.1 1878
All males 25 780 437 99 354 362 1 772 214 6.4 1.1 886 107
Females
 20–24 3 040 226 15 221 816 144 023 4.5 1.0 72 012
 25–29 2 401 996 15 231 600 118 851 4.7 1.0 59 426
 30–34 2 076 982 13 205 345 108 518 5.0 0.9 54 259
 35–39 1 579 019 10 145 572 86 319 5.2 0.8 43 160
 40–44 1 376 353 8 855 322 77 198 5.3 0.7 38 599
 45–49 1 246 144 6 346 512 72 214 5.5 0.5 36 107
 50–54 901 028 4 601 493 54 838 5.7 0.4 27 419
 55–59 404 381 2 905 416 25 928 6.0 0.3 12 964
 60–64 199 767 1 619 124 13 065 6.1 0.2 6533
 65–69 36 453 518 505 1975 5.1 0.0 988
All females 13 262 349 78 650 706 702 931 5.0 0.7 351 465
Total 39 042 786 178 005 069 2 475 144 6.0 1.0 1 237 572

Data are n or % of PALYs of life lost at current smoking prevalence, or potential PALY gained (n) with a hypothetical 50% reduction in smoking prevalence across all ages and sex.

PALY, productivity-adjusted life years.

As with years of life and QALYs, more PALYs were lost by males, because of their higher smoking prevalence, as well as by people of middle-age, because of the combination of greater smoking prevalence and proportion of people working in these age groups. In women, the highest proportional loss of PALYs occurred in those aged 45–64 years (table 5). The highest smoking prevalence among women was observed in the 45–54 years age group (table 1), suggesting that interventions to reduce smoking prevalence specifically targeted to this group could be prioritised. Among males, the highest smoking prevalence was observed in the 25–34 years age group (table 1), and the potential years of productive life gained through prevention targeting this group might also warrant focus.

Assuming the cost of each PALY is $A157 000, the total cost of productivity loss attributable to smoking was estimated to be $A388 billion over the working life of the current Australian population. If a 50% reduction in current smoking prevalence could be achieved, an additional 1 237 572 PALYs, and $A194 billion in GDP, could potentially be saved (table 6), but any savings would need to be offset by the cost of the prevention programme. Even more modest reductions in smoking prevalence (10%) could confer substantial lifetime productivity gains of >$A38 billion (table 6).

Discussion

The findings of our study highlight the substantial impact of smoking on health and productivity in the Australian population. Among Australians currently aged 20–69 years who are followed up to age 70 years, smoking was predicted to result in an excess of over 400 000 deaths, with a loss of >3 million years of life over the productive working age of current Australian smokers, and a 6% loss of PALYs, equating to $A388 billion lost in GDP.

Productivity losses accrued from a combination of premature mortality, morbidity-associated work absences (absenteeism) and reductions in productive capacity while at work (presenteeism). In our analyses, males and females who smoke were estimated to experience an almost threefold increase in the risk of death compared with people who do not smoke. This result is comparable to a study in 2015 on an Australian cohort population by Banks et al, which estimated smoking increases mortality around twofold to fourfold in current smokers.18 Our study estimated that current rates of smoking would cause >3 million years of life lost among 2.5 million Australian smokers aged 20–69 years when followed up until age 70 years. The 1997 Australian National Tobacco Campaign was estimated to have led to 190 000 people (of all ages) quitting smoking, and a gain of 323 000 years of life with follow-up until 85 years.19 Hence, each quitter gained 1.7 years of life until age 85 years. This estimate is in accord with our estimate of 1.2 years of life lost per smoker followed up for an overall shorter period of time from 20 to 69 years to 70 years.

In our study, the years of life lost was lower among females, due to a lower prevalence of smoking. As expected, years of life lost to smoking was also higher among younger age groups, because of higher smoking prevalence (particularly among men) and follow-up time within the modelled period.

Smoking is well known to decrease life expectancy. A study capturing 50 years of observation of male British doctors by Doll et al suggested that male smokers died on average 10 years earlier compared with non-smokers.20 A study in Chinese adults estimated smokers at age 35 years lost around 3 years of life when compared with people who never smoked,21 while in a Norwegian population it was estimated that 1.4–2.7 years of life were lost in heavy smokers aged 40–70 years.22 A recent study modelling average life expectancy in the Australian population by Mannan et al found that reducing the prevalence of smoking among Australian smokers to 10% would increase the life expectancy by 0.4–2 years for males and 0.7–2 years for females.23

Our study estimated that smoking would cause a loss of over 2.4 million PALYs among Australians currently aged 20–69 years who smoke, if followed up until age 70 years. This equated to 1.0 PALY lost per smoker. This compares with the loss of 1.4 PALYs per working age person with diabetes over a similar time horizon.8 The differences are attributable to a higher prevalence of diabetes than smoking and a greater reduction in productivity conferred by diabetes than smoking. Of course, this does not mean greater priority should be given to prevention of diabetes, which is more difficult to achieve given its multiplicity of risk factors, chief among which is genetic.

The loss of productivity, measured in terms of PALYs, among the working population has economic implications. Our study is the first to examine this cost in terms of PALYs, but previous studies have estimated the cost of productivity loss due to smoking via other means. In a study on the Australian population by Collins and Lapsley, it was estimated that smoking caused a loss of $A4.9 billion due to presenteeism (0.5% of GDP) and $A779 million due to absenteeism (0.08% of GDP) in the single financial year of 2004/2005.6 In 2000, Lightwood et al reported that the total economic costs of smoking, including productivity losses, amounted to 2.1%–3.4% of GDP in Australia.24 A study in Thailand reported that the economic burden of smoking was 0.8% of country GDP, while the revenue from tobacco industry only contributed to 0.5% of the total GDP.25 The results of our study are not directly comparable to those of other studies because of the differences in evaluation time horizons, which varied from 1 to 50 years in our study (depending on the age of the smokers), and which for other studies was limited to a single year. We had also adopted a simple ‘top-down’ approach to allocating total GDP to EFT worker. Nonetheless, our conclusion is the same as that of the other studies; that smoking imposes a large economic burden on productivity.

It is therefore clear that prevention of smoking is important from an economic standpoint. The high indirect costs of smoking suggest that it would be better for policy makers to consider the amount of money spent on prevention strategies as an ‘investment’ rather than as an ‘expenditure’.

Our study did not address the issue of smoking cessation. Rather, it sought to provide a conceptual illustration of the productivity losses due to smoking by assuming hypothetically that it did not exist, that is, smoking was not taken up in the first place. It should be acknowledged that this is a hypothetical scenario, and in reality, smoking cessation interventions as well as interventions or policy settings dissuading smoking uptake, would be required to aim for the productivity gains modelled herein, even those projected from more modest reductions in smoking prevalence. Smoking cessation is beneficial to productivity. A recent study in Japan suggested that smoking cessation improved productivity at work, with the productivity and associated costs of former smokers being similar to those who never smoked.26 This finding is supported by the findings of Baker et al, who found no significant difference between former and never smokers in term of productivity loss in China, the US and Europe.27 A 19-year follow-up study among males in Finland by Kiiskinen et al also stated that quitting smoking could avert almost 60% of losses due to the direct and indirect costs of smoking.28

Our study is the first to examine the impact of smoking on productivity in terms of PALYs, a novel and informative measure. Our method uses readily available data to estimate the macroeconomic productivity impact of smoking in a methodologically accessible manner, which could be applied in a variety of other country settings or risk/disease burdens. Further research using PALYs provides the opportunity to compare the effects of different tobacco control measures across various age, sex and employment settings, which can inform the targeting of interventions. In addition, application of this method across countries would provide a greater understanding of the regional and global indirect costs of smoking, and the potential productivity gains from tobacco control. Quantifying burden of disease in terms of PALYs can inform resource allocation and decision making for public and workplace health strategies, and may assist in leveraging employer engagement with tobacco control programmes.

PALYs are like QALYs because they ‘penalise’ time spent alive by people affected by a disease or condition, and do so in the same manner—by proportionally adjusting time according to the relative extent to which productivity (PALYs) or quality of life (QALYs) is affected by that disease or condition. QALYs have limitations that stem from their attempting to quantify the highly subjective nature of quality of life and how much people value it,29–31 but despite these limitations, they remain important measures of burden of disease that help inform healthcare planning. Furthermore, healthcare decision making does not rely on QALYs alone; many other factors need to be taken into consideration. As discussed, we feel that the impact of ill health on productivity should be among these factors, and PALYs offer a convenient method for measuring this. One advantage that PALYs have over QALYs is that the measurement and concept of productivity loss is much more objective than the the measurement and concept of quality of life.

Several limitations of our study warrant mention. First, our analyses did not take into account healthcare costs devoted to managing smoking-related ill health, which were estimated to be $A318 million in the year 2004/2005 (offset for savings accrued through premature mortality).6 Furthermore, potential gains from reductions in passive smoking-related mortality and morbidity, and productivity losses associated with family members caring for those with disabling smoking-related morbidity were also excluded. On the other hand, we did not consider the economic activity associated with production and sale of tobacco products, all of which contribute to GDP, nor government revenue generated from tobacco taxes.

Second, life table modelling is a simple and commonly used tool used in epidemiological and demographical studies, but has established limitations. It was assumed that age-specific mortality did not change over time (this is a well-known limitation called the ‘life table assumption’). However, as the relative impact of smoking is unlikely to change substantially, and the life table assumption was applied to both smokers and non-smokers, this would not have significantly impacted the conclusion that smoking imposes a significant burden on health and productivity. The third limitation stemmed from the assumption that there was no uptake nor cessation of smoking over time within the modelled scenarios. Furthermore, the utility values and productivity indices used in this study were potentially imprecise, as they were not stratified for type of work. The impact of smoking on productivity is likely to differ across different types of jobs, and socioeconomic status. Similarly, assessment of the quality of life differences between smokers and non-smokers (from which QALYs are calculated) can vary by instrument,32 and is also potentially confounded by socioeconomic factors such as educational attainment, household income and occupation.33 We could not account for the duration of smoking among smokers, nor any socioeconomic differences between smokers and non-smokers, and other factors that may confound the association between smoking and utilities and productivity indices.

Fourth, like QALYs, PALYs are imprecise because they attempt to measure entities that are difficult to measure. Nevertheless, even with highly conservative assumptions regarding the effect of smoking on productivity among individuals, the collective impact is large. And perhaps the imperfections of PALYs will help stir debate, as QALYs initially did 40 years ago,34 which in turn will progress the science, economics, art and politics of health-related productivity.

Lastly, in terms of estimating impact on GDP, the present study assumed that all individuals and jobs contributed equally to GDP, which is not the case, and we assumed throughout the simulated follow-up, GDP would be stable, rather than increase. This last assumption would have led to an underestimation of the economic impact of smoking.

The findings of our study provide an important and novel assessment of the burden of smoking on the Australian population. They highlight the importance of preventing smoking, strategies for which, if effective, are very likely to be cost-effective, and possibly even cost-saving, in the long term.35 This issue is even more telling for populations within which the prevalence of smoking is very high, and those low-income and middle-income countries for whom the burden of productivity loss may be considerable, such as Indonesia, a close neighbour to Australia, for which smoking prevalence rates among men is as high as 65%.36 Future studies may also consider the type of jobs in the ‘working’ population when calculating productivity loss, as prevalence rates of smoking, and salaries/GDP per worker may differ, and smoking has been shown to be socioeconomically patterned.37

Conclusion

Smoking imposes a very significant burden on the larger economy of Australia, despite that it is a country with a relatively low prevalence of smoking. Potential productivity gains for Australia with expansion of tobacco control measures are compelling. The likely economic benefits arising from productivity gains mean that greater investment in reducing the uptake of smoking is warranted.

What this paper adds.

  • Direct healthcare costs attributable to smoking are only a proportion of the economic burden imposed by tobacco.

  • This study uses the novel concept of ‘productivity-adjusted life years’ (PALYs) to estimate the macroeconomic costs of smoking, and potential gains from smoking cessation.

  • Following the current Australian smoking population to the age of 70 years, 2.4 million PALYs would be lost to smoking.

  • Assuming that each PALY in Australia is equivalent to $A157 000 (gross domestic product per equivalent full-time worker in 2016), the economic impact of lost productivity over the working lifetime of current Australian smokers would amount to $A388 billion.

Footnotes

Contributors: AJO had the primary responsibility for writing this paper, in collaboration with SBM. All authors (AJO, SBM, EZ, DL) contributed to development and design of the model, interpretation of the results and review and comment on drafts of the paper. DL designed and supervised the study.

Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: None declared.

Patient consent: Not required.

Ethics approval: This study was approved by the Monash University Human Research Ethics Committee (ref# 8895) as a low-risk project.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: All data have been obtained from publicly available sources.

References

  • 1. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:2287–323. 10.1016/S0140-6736(15)00128-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Intergovernmental Committee on Drugs. National Tobacco Strategy 2012-18. Canberra, Australia, 2013. [Google Scholar]
  • 3. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014;311:183–92. 10.1001/jama.2013.284692 [DOI] [PubMed] [Google Scholar]
  • 4. Australia’s Health. Australian Institute of Health and Welfare (AIHW). 2016. https://www.aihw.gov.au/getmedia/9d29c844-57b0-4d68-808b-2dfd13aec28c/ah16-4-7-tobacco-smoking.pdf.aspx
  • 5. Goodchild M, Nargis N, Tursan d’Espaignet E. Global economic cost of smoking-attributable diseases. Tob Control 2018;27:58–64. 10.1136/tobaccocontrol-2016-053305 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Collins DJ, Lapsley HM. The costs of tobacco, alcohol & illicit drug abuse to Australian society in 2004/05: Commonwealth of Australia, 2008. http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.nsf/Content/mono66/$File/mono66.pdf. [Google Scholar]
  • 7. Ahmad S. Increasing excise taxes on cigarettes in California: a dynamic simulation of health and economic impacts. Prev Med 2005;41:276–83. 10.1016/j.ypmed.2004.10.024 [DOI] [PubMed] [Google Scholar]
  • 8. Magliano DJ, Martin VJ, Owen AJ, et al. The productivity burden of diabetes at a population level. Diabetes Care 2018;41:979–84. 10.2337/dc17-2138 [DOI] [PubMed] [Google Scholar]
  • 9. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press, 2006. [Google Scholar]
  • 10. Jia H, Lubetkin EI. Trends in quality-adjusted life-years lost contributed by smoking and obesity. Am J Prev Med 2010;38:138–44. 10.1016/j.amepre.2009.09.043 [DOI] [PubMed] [Google Scholar]
  • 11. Bunn WB, Stave GM, Downs KE, et al. Effect of smoking status on productivity loss. J Occup Environ Med 2006;48:1099–108. 10.1097/01.jom.0000243406.08419.74 [DOI] [PubMed] [Google Scholar]
  • 12. Australian Institute of Health and Welfare. Australian Institute of Health and Welfare General record of incidence of mortality books, Canberra, Australia, 2015. [Google Scholar]
  • 13. Australian Bureau of Statistics. National Health Survey: first results, Australia 2014-15. 2017:30–2 http://www.abs.gov.au/ausstats/abs@.nsf/mf/4364.0.55.001
  • 14. Peto R, Lopez AD, Boreham J, et al. Mortality from Smoking in Developed Countries 1950−2000. http://www.deathsfromsmoking.net/2006
  • 15. Australian Bureau of Statistics. Characteristics of employment. Australia: Australian Bureau of Statistics, 2016. [Google Scholar]
  • 16. Weng SF, Ali S, Leonardi-Bee J. Smoking and absence from work: systematic review and meta-analysis of occupational studies. Addiction 2013;108:307–19. 10.1111/add.12015 [DOI] [PubMed] [Google Scholar]
  • 17. The World Bank. Current gross domestic product-data. 2016. https://data.worldbank.org
  • 18. Banks E, Joshy G, Weber MF, et al. Tobacco smoking and all-cause mortality in a large Australian cohort study: findings from a mature epidemic with current low smoking prevalence. BMC Med 2015;13:38 10.1186/s12916-015-0281-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Hurley SF, Matthews JP. Cost-effectiveness of the Australian National Tobacco Campaign. Tob Control 2008;17:379–84. 10.1136/tc.2008.025213 [DOI] [PubMed] [Google Scholar]
  • 20. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519 10.1136/bmj.38142.554479.AE [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Jiang J, Liu B, Sitas F, et al. Smoking-attributable deaths and potential years of life lost from a large, representative study in China. Tob Control 2010;19:7–12. 10.1136/tc.2009.031245 [DOI] [PubMed] [Google Scholar]
  • 22. Vollset SE, Tverdal A, Gjessing HK. Smoking and deaths between 40 and 70 years of age in women and men. Ann Intern Med 2006;144:381–9. 10.7326/0003-4819-144-6-200603210-00004 [DOI] [PubMed] [Google Scholar]
  • 23. Mannan H, Curtis AJ, Forbes A, et al. Improvements in life expectancy among Australians due to reductions in smoking: Results from a risk percentiles approach. BMC Public Health 2016;16:77 10.1186/s12889-016-2750-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Lightwood J, Collins DJ, Lapsley HM, et al. Estimating the costs of tobacco use. New York: Oxford University Press, 2000. [Google Scholar]
  • 25. Bundhamcharoen K, Aungkulanon S, Makka N, et al. Economic burden from smoking-related diseases in Thailand. Tob Control 2016;25:532–7. 10.1136/tobaccocontrol-2015-052319 [DOI] [PubMed] [Google Scholar]
  • 26. Suwa K, Flores NM, Yoshikawa R, et al. Examining the association of smoking with work productivity and associated costs in Japan. J Med Econ 2017;20:938–44. 10.1080/13696998.2017.1352507 [DOI] [PubMed] [Google Scholar]
  • 27. Baker CL, Flores NM, Zou KH, et al. Benefits of quitting smoking on work productivity and activity impairment in the United States, the European Union and China. Int J Clin Pract 2017;71:e12900 10.1111/ijcp.12900 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Kiiskinen U, Vartiainen E, Puska P, et al. Smoking-related costs among 25 to 59 year-old males in a 19-year individual follow-up. Eur J Public Health 2002;12:145–51. 10.1093/eurpub/12.2.145 [DOI] [PubMed] [Google Scholar]
  • 29. Soares MO. Is the QALY blind, deaf and dumb to equity? NICE’s considerations over equity. Br Med Bull 2012;101:17–31. 10.1093/bmb/lds003 [DOI] [PubMed] [Google Scholar]
  • 30. Vallejo-Torres L, García-Lorenzo B, Castilla I, et al. On the estimation of the cost-effectiveness threshold: why, what, how? Value Health 2016;19:558–66. 10.1016/j.jval.2016.02.020 [DOI] [PubMed] [Google Scholar]
  • 31. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 2010;96:5–21. 10.1093/bmb/ldq033 [DOI] [PubMed] [Google Scholar]
  • 32. Feirman SP, Glasser AM, Teplitskaya L, et al. Medical costs and quality-adjusted life years associated with smoking: a systematic review. BMC Public Health 2016;16:646 10.1186/s12889-016-3319-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Luo N, Johnson JA, Shaw JW, et al. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 2005;43:1078–86. 10.1097/01.mlr.0000182493.57090.c1 [DOI] [PubMed] [Google Scholar]
  • 34. Pliskin JS, Shepard DS, Weinstein MC. Utility functions for life years and health status. Oper Res 1980;28:206–24. 10.1287/opre.28.1.206 [DOI] [Google Scholar]
  • 35. Ekpu VU, Brown AK. The Economic impact of smoking and of reducing smoking prevalence: review of evidence. Tob Use Insights 2015;8:1–35. 10.4137/TUI.S15628 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. World Health Organization. WHO report on the global tobacco epidemic. 2017. http://www.who.int/tobacco/surveillance/policy/country_profile/idn.pdf
  • 37. Stringhini S, Carmeli C, Jokela M, et al. Socioeconomic status and the 25×25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1·7 million men and women. Lancet 2017;389:1229–37. 10.1016/S0140-6736(16)32380-7 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary data

tobaccocontrol-2018-054263supp001.pdf (84.4KB, pdf)


Articles from Tobacco Control are provided here courtesy of BMJ Publishing Group

RESOURCES